Preliminary Study on Human Papillomavirus Frequency and Specific Type-distribution in Vulva Cancer from Thai Women

  • Published : 2013.04.30


Vulva cancer is rare among all gynecological cancer worldwide, including Thailand, and mainly affects older women. Persistent high risk type infection of human papillomavirus (HPV) is the one important factor for developing cancer. In this study, we focused on HPV DNA investigation and type-specific distribution of HPV in 25 formalin-fixed paraffin-embedded (FFPE) samples collected from Thai women with vulva cancer histologically confirmed by the National Cancer Institute, Thailand, during 2003-2011. HPV DNA detection and genotyping were undertaken with polymerase-chain reaction and enzyme-immunoassay using GP5+/bio6+ consensus specific primers and digoxigenin-labeled specific oligoprobes, respectively. Human ${\beta}$-globin genes was used as the internal control. Our results showed that 44% (11/25) of all vulva cancer samples were HPV-positive. All of them are high risk HPV type infection, detected as single (63.64%, 7/11) and/or double infections (4/11, 36.36%). HPV 16 was the most common type identified in vulva cancer, followed by HPV 35, 33, 18 and 58. In conclusion, this study presented that HPV-16 is observed at the highest frequency in this cancer, similar to cervical cancer, with HPV 18 being less frequent. Although the sample size was small and could not represent overall incidence and prevalence in Thai women, these preliminary data for vulva cancer are of interest since they reinforce the necessity for HPV screening or vaccination in Thailand.


  1. Baldez da Silva MF, Guimaraes V, Silva MAR, et al (2012). Frequency of human papillomavirus types 16, 18, 31 and 33 and sites of cervical lesions in gynecological patients from Recife, Brazil. Genet Mol Res, 11, 462-6.
  2. De Vuyst H, Clifford GM, Nascimento MC, et al (2009). Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anal: a meta-analysis. Int J Cancer, 124, 1626-36.
  3. Dittmer C, Katalinic A, Mundhenke C et al (2011). Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet, 284, 169-74.
  4. Fox H, Wells M (2003). Recent advances in the pathology of the vulva, Histopathology, 42, 209-16.
  5. Gil-Prieto R, Bordoy JC, Ramon y Cajal JM et al (2011). Hospialization in Spain associated with malignant neoplasia of the vulva and vagina (1997-2008). Human Vaccines, 7, 856-63.
  6. Giuliano AR, TortoleroLuna G, ferrer E et al (2008). Epidemiology of Human Papillomavirus Infection in Men, Cancer other than Cervical and Benign Conditions. Vaccine, 26, 17-28.
  7. Hampl M, Sarajuuri H, Wentzensen N, et al (2006). Effect of human papillomavirus vaccines on vulvar, vaginal and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol, 108, 1361-8.
  8. Hampl M, Wentzensen N, Vinokurova S, et al (2007). Comprehensive analysis of 130 multicantric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol, 133, 235-45.
  9. Hording U, Junge J, Daugaard S, et al (1994). Vulvar squamous cell carcinoma and papilomavirus: indications for two different etiologies. Gynecol Oncol, 52, 241-6.
  10. Jacob MV, Snijder PJ, van den Brule AJ, et al (1997). A general primer GP5+/6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol, 35, 791-5.
  11. Jacob MV, van der Brule AJ, Snijder PJ, et al (1996). A nonradioactive PCR enzyme-Immunoassay enables a rapid identification of HPV16 and 18 in cervical scrapes after GP5+/6+ PCR. J Med Virol, 49, 223-9.<223::AID-JMV11>3.0.CO;2-D
  12. Jacob MV, Walboomers JM, Snijder PJ, et al (2000). Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related pattern for high-risk and low-risk types. Int J Cancer, 87, 221-7.<221::AID-IJC11>3.0.CO;2-2
  13. Jones RW, Sadler L, Grant S, et al (2004). Clinical identifying women with vulvar lichen sclerosus at increased risk of squamous cell carcinoma: a case-control study. J Reprod Med, 49, 808-11.
  14. Karunaratne K (2011). Review: squamous-cell vulvar cancer. Sri Lanka J Obstet Gynecol, 33, 30-2.
  15. Khuhaprema T, Attasara P, Sriplung H, et al (2012). Cancer in Thailand Vol VI 2004-2006, Bangkok, Thailand, 3-68.
  16. Madeleine MM, Daling JR, Carter JJ, et al (1997). Cofactor with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst, 89, 1516-23.
  17. Monk BJ, Burger RA, Lin F, et al (1995). Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol, 85, 709-15.
  18. Munger K, Baldwin A, Edwards KM, et al (2004). Mechanisms of human papillomavirus-induced oncogenesis. J Virol, 78, 11451-60.
  19. Parkin DM (2002). The global health burden of infectionassociated cancer in the Year 2002. Int J Cancer, 118, 3030-44.
  20. Ramet J, van Esso D, Meszner Z, et al (2010). Position paper-HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians. Eur J Pediatr, 170, 309-21.
  21. Ruhul QM, Xu C, Steinhoff MM, et al (2005). Simplex (differentiated) type VIN: absence of p16INK4 supports its weak association with HPV and its probable precursor role in non-HPV related vulvar squamous cancer. Histopathology, 46, 718-20.
  22. Sankaranarayanan R, Feray J (2006). Worldwide burden of gynecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25.
  23. Shukla S, Bharti AC, Mahata S, et al (2009). Infection of human papillomivirus in cancers of different human organ sites. Indian J Med Res, 130, 222-33.
  24. Smith J, Backes D, Hoots B, et al (2009). Human papilloma virus type-distributon in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol, 113, 917-24.
  25. Terlou A, Blok LJ, Helmerhorst TJM, et al (2010). Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget's disease and melanoma in situ. Acta Obstetricia et Gynecologica, 89, 741-8.
  26. Trimble CL, Hildesheim A, Brinton LA, et al (1996). Heterogeneous etiology of squamous carcinoma of the vulva, Obstet Gynecol, 87, 59-64.
  27. van de Nieuwenhof, van der Avoort IA, de Hullu JA, et al (2008). Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol, 68, 131-56.
  28. van der Avoort I, Shirango H, Hoevenaars BM, et al (2006). Vulvar squamous cell carcinoma is a multifactorial disease following two separate and indepenedent pathways. Int J Gynecol Pathol, 25, 22-9.
  29. Walboomers JM, Jacobs MV, Manos MM et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  30. WHO/ICO Information Center on HPV and Cervical Cancer (HPV Information Center) (2010). Human Papillomavirus ad Related Cancer in World; Summary Report 2010. Available at, Access on February 22, 2013.
  31. Yang B, Hart WR (2000). Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am J Surg Pathol, 24, 429-41.
  32. zur Hausen H (2002). Papillomavirus and cancer: from basic studies to clinical application. Nature Reviews, 2, 342-50.

Cited by

  1. Prevalence of High Risk Human Papillomavirus Infection with Different Cervical Cytological Features among Women Undergoing Health Examination at the National Cancer Institute, Thailand vol.15, pp.14, 2014,
  2. HPV Detection and Genotyping in Vulvar Squamous Cell Carcinoma in Northern Thailand vol.15, pp.8, 2014,
  3. Detection and Type-Distribution of Human Papillomavirus in Vulva and Vaginal Abnormal Cytology Lesions and Cancer Tissues from Thai Women vol.17, pp.3, 2016,